Make it stand out.
Intuitive Surgical · Global Evidence Management
Robotic Surgery
Clinical Evidence Navigator
Clinical Evidence Navigator
Systematic literature review & meta-analysis · da Vinci surgical systems · Five common general surgery procedures
135+ publications reviewed
7+ million patients
Data through April 2024
RCT + observational evidence
Cholecystectomy
31 publications
No RCTs — observational evidence only
Data through April 15, 2024
Conversion reduction
−49%
2.6% vs 6.3% (lap)
EBL reduction
−7.65 mL
14.8 vs 22.5 mL
Operative time penalty
+9.8 min
97 vs 87 min (lap faster)
Length of stay
Equal
2.0 vs 2.3 days (NS)
Favors robotic
↓Conversions to open by 49%
↓Estimated blood loss by 7.65 mL
Comparable outcomes
≈Blood transfusion (1.9% vs 1.9%)
≈Bile duct injury (0.7% vs 0.5%)
≈Bile duct leak (1.5% vs 0.6%)
≈Bile duct obstruction (0.7% vs 0.7%)
≈Surgical site infection (1.3% vs 1.3%)
≈30-day complications (13.3% vs 12%)
≈30-day readmissions (5.7% vs 5.7%)
≈30-day reoperations (1.4% vs 1.4%)
≈30-day mortality (1.2% vs 1.4%)
Favors laparoscopic
↓Operative time 9.81 min shorter
Clinical takeaway: Robotic cholecystectomy cuts conversion risk by nearly half and reduces blood loss modestly. All critical safety metrics — bile duct injury, SSI, mortality — are statistically equivalent to laparoscopic. Laparoscopy remains ~10 minutes faster. No RCTs exist; interpret as observational evidence only.
SSI reduction
−72%
2.1% vs 7.0%
LOS reduction
−3.5 days
3.0 vs 6.5 days
30-day mortality
−55%
4.3% vs 8.2%
30-day complications
−45%
19.8% vs 30.8%
Favors robotic
↓SSI by 72%
↓Blood transfusion by 60%
↓LOS by 3.5 days
↓30-day complications by 45%
↓30-day mortality by 55%
Comparable outcomes
≈Bile duct injury (0.7% vs 2.0%)
≈30-day readmissions (10.5% vs 18.7%)
≈30-day reoperations (2.3% vs 3.1%)
Favors open
None identified
Clinical takeaway: Robotic (and by extension laparoscopic) dominates open across every safety metric. Based on only 3 studies — findings are consistent with the established minimally invasive advantage over open surgery.
Elective — 7 studies
↓Conversions by 89%
↓EBL by 14.3 mL
↓30-day readmissions by 52%
≈Bile duct injury & bile duct leak
≈30-day complications & LOS
↑Op time +10.37 min longer
Emergent / Urgent — 7 studies
↓Conversions by 43%
↓EBL by 10.6 mL
≈Operative time
≈LOS, SSI, bile duct injury
≈30-day complications, readmissions, mortality
≈30-day reoperations
EGS relevance: In emergent and urgent cases, robotic maintains its conversion advantage with no degradation of any safety metric — and the operative time penalty seen in elective cases disappears entirely. This supports the evidence base for after-hours robotic emergency general surgery programs.
Ventral Hernia Repair
35 publications
5 RCTs — PROVE-IT, RIVAL + others
Data through March 1, 2024
2-year recurrence reduction
−87%
OR 0.23 · RCT supported
SSI reduction (30-day)
−56%
OR 0.44
Conversion reduction
−46%
OR 0.54
Op time (lap faster)
−59 min
Laparoscopic advantage
Favors robotic
↓2-year hernia recurrence by 87%
↓30-day SSI by 56%
↓Conversions by 46%
↓30-day VAS pain by 0.8 points
Comparable outcomes
≈Pain medication at discharge
≈Length of hospital stay
≈Time to return to activities
≈30-day complications
≈30-day readmissions & reoperations
≈30-day hernia recurrence
≈HerQLes quality of life score
≈30-day mortality
Favors laparoscopic
↓Operative time 59 min shorter
Strongest evidence base of the five procedures: 5 RCTs support these findings. The 87% reduction in 2-year hernia recurrence is the most compelling single outcome across all procedures reviewed — and recurrence is the metric patients and payers weigh most heavily for hernia surgery. The operative time disadvantage is the primary tradeoff.
LOS reduction
−2.6 days
p<0.01
SSI reduction
−72%
OR 0.28
Readmission reduction
−29%
OR 0.71
30-day recurrence
−84%
OR 0.16
Favors robotic
↓LOS by 2.6 days
↓SSI by 72%
↓30-day readmissions by 29%
↓30-day hernia recurrence by 84%
↓30-day mortality risk (p<0.01)
Comparable outcomes
≈Pain medication at discharge
≈Time to return to activities
≈30-day reoperations
≈HerQLes quality of life score
≈30-day complications
Favors open
↓Operative time 93 min shorter
Clinical takeaway: Robotic wins comprehensively vs open on every safety and outcome metric. The 93-minute operative time difference is the sole tradeoff — expected for any MIS vs open comparison and consistent across all procedures reviewed.
Inguinal Hernia Repair
40 publications
2 RCTs — RIVAL trial
Data through March 1, 2024
1-year recurrence reduction
−49%
0.7% vs 2.3%
≥2-year recurrence reduction
−51%
1.1% vs 2.0%
Conversion reduction
−53%
2.1% vs 2.8%
Op time (unilateral)
+19 min
80.6 vs 61.5 min
Favors robotic
↓1-year recurrence by 49%
↓≥2-year recurrence by 51%
↓Conversions by 53%
↓24-hr VAS pain by 1.02 pts (2.4 vs 3.4)
Comparable outcomes
≈EBL (4.7 vs 5.8 mL)
≈Blood transfusions (0% vs 0.1%)
≈SSI (2.1% vs 2.0%)
≈Inpatient LOS (1.6 vs 1.5 days)
≈30-day complications, readmissions, mortality
≈1-year VAS pain & 2-year chronic pain
Favors laparoscopic
↓Unilateral op time 19.08 min shorter
↓Bilateral op time 21.42 min shorter
Durable recurrence advantage: The 49–51% reduction in hernia recurrence at 1 and 2+ years is supported by the RIVAL RCT and large database studies. Recurrence drives reoperation, disability, and downstream cost — making this the primary value argument for robotic inguinal hernia repair over laparoscopic.
24-hr VAS pain reduction
−3.37 pts
0 vs 3.4 score
30-day acute pain reduction
−68%
1.4% vs 4.3%
Op time (unilateral)
+23 min
84.4 vs 61.4 min
1-yr recurrence
Equal
1.4% vs 3.4% (NS)
Favors robotic
↓24-hr VAS pain by 3.37 points
↓30-day acute pain by 68%
Comparable outcomes
≈Blood transfusions & SSI
≈LOS (inpatient & outpatient)
≈30-day complications, readmissions, mortality
≈1-year and ≥2-year recurrence
Favors open
↓Unilateral op time 22.96 min shorter
↓Bilateral op time 26.69 min shorter
Clinical takeaway: The primary advantage vs open is dramatically lower early postoperative pain. Recurrence is statistically equivalent at 1–2 years in this comparison; the recurrence benefit is most pronounced in the robotic vs laparoscopic comparison.
Right Colectomy
18 publications
2 RCTs included
Data through March 1, 2024
Conversion reduction
−43%
6% vs 10%
Ileus reduction
−21%
9.4% vs 11.5%
Anastomotic leak reduction
−11%
4.8% vs 5.3%
LOS reduction
−0.48 days
4.5 vs 5.0 days
Favors robotic
↑Lymph node yield +1.15 nodes (22.8 vs 21.7)
↓EBL by 15.79 mL (69.5 vs 85.3 mL)
↓Conversions by 43%
↓Ileus by 21%
↓Anastomotic leak by 11%
↓LOS by 0.48 days
Comparable outcomes
≈Blood transfusions (7.7% vs 6.9%)
≈Proximal & distal resection margins
≈Time to flatus (2.5 vs 2.3 days)
≈30-day complications (20.6% vs 21.7%)
≈30-day readmissions (6.8% vs 7.3%)
≈30-day reoperations (5.7% vs 5.4%)
≈30-day mortality (0.7% vs 0.8%)
≈SSI (3.0% vs 2.9%)
Favors laparoscopic
↓Operative time 56 min shorter (171 vs 228 min)
Clinical takeaway: The anastomotic leak reduction (−11%) and ileus reduction (−21%) are clinically meaningful — both drive LOS and reoperation rates. The lymph node yield advantage (+1.15 nodes) has oncologic relevance; NCCN minimum is 12 nodes. The 56-minute operative time penalty is the largest across all five procedures reviewed.
LOS reduction
−2.5 days
4.9 vs 7.4 days
Ileus reduction
−36%
9.9% vs 14.7%
30-day reoperations
−15%
5.9% vs 6.9%
LN yield advantage
+0.4 nodes
20.6 vs 20.1
Favors robotic
↑Lymph node yield +0.4 nodes
↓Ileus by 36%
↓LOS by 2.5 days
↓30-day reoperations by 15%
Comparable outcomes
≈30-day mortality (0.6% vs 0.8%)
Favors open
↓Operative time 85 min shorter
Clinical takeaway: Limited to 6 studies. Robotic shows substantial LOS and ileus advantage. Note that open patients in database studies frequently carry higher comorbidity burdens — selection bias likely influences these estimates and should temper interpretation.
Sigmoidectomy for Diverticular Disease
12 publications
No RCTs — Level 2c / 3b only
No open comparator
Data through March 1, 2024
Conversion reduction
−54%
OR 0.46
SSI reduction
−46%
OR 0.54
30-day complications
−23%
OR 0.77
LOS reduction
−0.4 days
p<0.01
Favors robotic
↓Conversions by 54%
↓SSI by 46%
↓30-day complications by 23%
↓LOS by 0.4 days
Comparable outcomes
≈EBL & blood transfusions
≈Anastomotic leak
≈Major complications
≈Ileus & stoma formation rates
≈30-day reoperations
≈30-day readmissions & mortality
Favors laparoscopic
↓Operative time 35.81 min shorter
Smallest evidence base of the five procedures — 12 studies, no RCTs, no open comparator. The directional findings are consistent with the broader colorectal robotic literature: conversion, SSI, and complication benefits are reproducible across procedure types. Interpret with appropriate caution given the observational-only evidence level.